| Why do we need a statin trial in hemodialysis patients? | |
| | |
MedLine Citation:
|
PMID: 12694345 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The risk of cardiovascular complications is markedly increased in patients on dialysis treatment. This includes cardiac disease, stroke, and peripheral vascular disease. The mortality in dialysis patients is markedly higher compared to a nonuremic population. There are several cardiovascular (CV) risk factors that are unique to this population, one of which is dyslipidemia. Uremic patients do not usually develop hypercholesterolemia, but rather are characterized by high levels of very low density lipoprotein (VLDL) triglycerides, low high density lipoprotein (HDL) cholesterol, and elevated levels of modified low density lipoprotein (LDL) particles, which are particularly harmful to the vascular wall. HMG-CoA reductase inhibitors (statins) have been proven to be very efficient in reducing CV events in a nonrenal population. There are several landmark trials that have demonstrated that statins reduce the mortality in cardiovascular disease (CVD) in populations with normal, or close to normal, renal function. There are some observational registry data indicating that this may also be true in hemodialysis (HD) patients, but no prospective controlled trial has been performed to date. METHODS: We present the rationale for, and a brief outline of, a randomized placebo-controlled trial using a novel drug, rosuvastatin, in HD patients, to target cardiovascular events (the AURORA study). This study will include close to 3000 male and female HD patients, aged 50-80 years. The study is event driven and it has been estimated that it will run for a follow-up time close to four years. CONCLUSION: There is a sound rationale for making a randomized placebo-controlled statin trial in HD patients, with the objective to demonstrate an effect on CV mortality and morbidity. |
| | |
Authors:
|
Bengt C Fellström; Hallvard Holdaas; Alan G Jardine |
Related Documents
:
|
7728915 - Lipid patterns in patients with chronic occlusive arterial disease affecting lower limbs. 21809045 - Evaluation of lasting high levels of crp among the patients with metabolic syndrome. 22205695 - Growth-differentiation factor-15 in the early diagnosis and risk stratification of pati... 22204855 - The obesity paradox in heart failure: is etiology a key factor? 10867455 - Preoperative ercp approach to common bile duct stones: results of a selective policy. 22930515 - Molecular and phylogenetic analyses of human parvovirus b19 isolated from brazilian pat... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Kidney international. Supplement Volume: - ISSN: 0098-6577 ISO Abbreviation: Kidney Int. Suppl. Publication Date: 2003 May |
Date Detail:
|
Created Date: 2003-04-15 Completed Date: 2003-07-16 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7508622 Medline TA: Kidney Int Suppl Country: United States |
Other Details:
|
Languages: eng Pagination: S204-6 Citation Subset: IM |
Affiliation:
|
Department of Medicine, Western Infirmary, Glasgow, United Kingdom. Bengt.Fellstrom@medsci.uu.se |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antilipemic Agents
/
therapeutic use* Fluorobenzenes / therapeutic use* Humans Hyperlipidemias / drug therapy*, epidemiology Kidney Failure, Chronic / epidemiology, therapy* Pyrimidines* Randomized Controlled Trials as Topic / methods Renal Dialysis* Risk Factors Sulfonamides* Uremia / epidemiology, therapy |
| Chemical | |
Reg. No./Substance:
|
0/Antilipemic Agents; 0/Fluorobenzenes; 0/Pyrimidines; 0/Sulfonamides; 287714-41-4/rosuvastatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cardiovascular risk factors in predialysis patients: baseline data from the Chronic Renal Impairment...
Next Document: Study of Heart and Renal Protection (SHARP).